Associated Skin Care Specialists | Minnesota Clinical Study Center

Research site
119 14th St NW, New Brighton, Minnesota, United States of America
Site insights

Top conditions

Psoriasis (8 trials)

Dermatitis (5 trials)

Eczema (5 trials)

Atopic Dermatitis (5 trials)

Hidradenitis Suppurativa (3 trials)

Top treatments


Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


15 of 32
Status: Active
Trial type: Interventional
Funder type: Industry

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD....

Active, not recruiting
Atopic Dermatitis
Drug: Difamilast

The main purpose of this study is to assess the change in clinician global impression after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrou...

Not yet enrolling
Microcystic Lymphatic Malformation
Drug: Placebo
Drug: QTORIN 3.9% Rapamycin Anhydrous Gel

PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A,...

Pachyonychia Congenita
Drug: PTX-022

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Drug: Placebo
Drug: Upadacitinib

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Alopecia Areata
Drug: Placebo
Drug: Upadacitinib

The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle g...

Active, not recruiting
Seborrheic Keratosis
Drug: Vehicle gel
Drug: SM-020 gel 1.0%

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face o...

Gorlin Syndrome
Drug: Patidegib Topical Gel with no active patidegib
Drug: Patidegib Topical Gel

This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness...

Distal Lateral Subungual Onychomycosis
Device: Nail Genesis DLSO Product
Device: Nail Genesis DLSO Product (vehicle only)

The purpose of this extension study is to evaluate maintenance of HiSCR response in either continuous or interrupted therapy (using a randomized with...

Active, not recruiting
Hidradenitis Suppurativa
Drug: secukinumab

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Drug: BMS-986165

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Discoid Lupus Erythematosus
Drug: Daxdilimab
Drug: Placebo/Daxdilimab

Trial sponsors

AbbVie logo

AbbVie (5 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems